Introduction
============

The human *GSTP1* gene is located on chromosome 11 (11q13.2) ([@B44]), and the GSTP1 (Glutathione *S*-Transferase pi) protein participates in the drug resistance process of cancer cells ([@B45]). Two commonly occurring polymorphisms within the exon 5/6 region of the *GSTP1* gene, namely, rs1695 (A313G, IIe105Val) and rs1138272 (C341T, Ala114Val), may be related to the occurrence and development of certain diseases ([@B16]; [@B58]; [@B49]; [@B64]; [@B54]). For instance, the *GSTP1* rs1695 polymorphism is likely associated with the risk of Alzheimer's disease, based on a previous meta-analysis ([@B54]). There have been several comprehensive analyses concerning the potential role of the *GSTP1* rs1695 polymorphism in the susceptibility to cancer. However, the results varied between cancer types. For example, *GSTP1* rs1695 was reported to be associated with the risk of esophageal cancer and malignant melanoma in the Caucasian population ([@B49]; [@B64]), but not childhood acute lymphoblastic leukemia (ALL) ([@B63]) or bladder cancer ([@B62]). To the best of our knowledge, very limited comprehensive analyses on the relationship between *GSTP1* rs1138272 and overall cancer risk have been reported.

[@B16], one relevant meta-analysis containing 28 case-control studies was reported, assessing the potential effect of the *GSTP1* rs1138272 C/T polymorphism on the risk of overall cancer. In view of the publication of new relevant articles in the last 5 years, we performed an updated meta-analysis to gain insight into the genetic association between the rs1138272 C/T polymorphism of the *GSTP1* gene and the risk of cancer. Altogether, 43 eligible case-control studies were recruited into our statistical analysis.

Materials and Methods {#s1}
=====================

Database Searching
------------------

Five online databases extending until September 2018, including PubMed, Embase, Cochrane, Scopus, and WOS (web of science), were utilized for the article identification. Referring Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ([@B33]) were considered. The search terms are shown in Supplementary Table [S1](#TS1){ref-type="supplementary-material"}.

Screening Process
-----------------

First, duplicate articles or articles with overlapping data were removed. In addition, review articles, meta-analyses, meeting abstracts and case reports were excluded. Articles that lacked normal control data or the complete genotype data on the CC, CT, TT status of *GSTP1* rs1138272 in the cases/controls were also removed. The basic information was then collected and summarized, and *P*-HWE (*P*-value for Hardy--Weinberg equilibrium) was calculated. The quality appraisal of each study was also performed using the Newcastle-Ottawa Scale (NOS) system. Articles with *P*-HWE \> 0.05 for the controls and an NOS score \> = 5 were included. Eligible case-control studies were finally considered.

Statistical Tests
-----------------

A fixed-effects model was applied in the Mantel--Haenszel statistics of association test when the *P*-heterogeneity of Cochran's Q statistic was larger than 0.1 or the I^2^ value was less than 50%. When those criteria were not met, a random effects model was used in the DerSimonian and Laird statistics of association test. For the assessment of the pooled effect size, we obtained the odds ratio (OR), 95% confidence interval (CI) and *P*-Association (*P*-value of association test) from each meta-analysis and subsequent subgroup analysis by ethnicity, control source, or cancer type.

We used the Begg's and Egger's tests to assess the potential publication bias when the number of enrolled case-control studies was larger than 10. We also performed a sensitivity analysis to evaluate the data stability and possible sources of heterogeneity. The STATA software (version 12.0, StataCorp, United States) was used to analyze the following genetic models in the association test, Begg's test, Egger's test, and sensitivity analysis: the allele model (allele T vs. allele C), homozygote model (TT vs. CC), heterozygote model (CT vs. CC), dominant model (CT+TT vs. CC), recessive model (TT vs. CC+CT), and carrier model (carrier T vs. carrier C).

Results
=======

Case-Control Study Recruitment
------------------------------

A flow chart illustrating the process of study selection is presented in Figure [1](#F1){ref-type="fig"}. Briefly, we initially obtained a total of 2,804 records by searching five databases, including 736 records from PubMed, 484 records from Embase, 60 records from Cochrane, 723 records from Scopus and 801 records from WOS. Then, we removed 1,202 duplicate records and excluded the following 1,506 records: 158 reviews; 70 meta-analyses; 42 case reports; 160 meeting abstracts; 62 articles with data on mouse, rat or dog models; 111 articles with *in vitro* data on cell lines; 792 articles focusing on other diseases, other genes or other variants of the *GSTP1* gene; and 111 articles containing data on methylation or gene expression. Next, we assessed the eligibility of the remaining 96 full-text articles. An additional 56 articles were excluded, including 56 articles with unavailable data on the genotype frequency of CC, CT, and TT within *GSTP1* rs1138272, and 4 articles in which the data were not in HWE. After a quality evaluation, 40 articles ([@B15]; [@B40]; [@B38]; [@B52]; [@B56]; [@B31]; [@B48]; [@B20]; [@B55], [@B53]; [@B47]; [@B60]; [@B11]; [@B23], [@B24]; [@B34]; [@B5]; [@B28]; [@B29]; [@B18]; [@B26], [@B25]; [@B35]; [@B1]; [@B21]; [@B46]; [@B50]; [@B65]; [@B3]; [@B36]; [@B42]; [@B8]; [@B12]; [@B17]; [@B7]; [@B37]; [@B14]; [@B4]; [@B32]; [@B39]) of good quality were included. Finally, we included a total of 43 case-control studies for our quantitative synthesis. All of the data in these articles were in HWE. The detailed characteristics of these articles are provided in Table [1](#T1){ref-type="table"}.

![Selection process for eligible case-control studies.](fphys-09-01897-g001){#F1}

###### 

Characteristics of the included studies.

  First author   Year   Ethnicity   CC-CT-TT (case)   Cancer type            CC-CT-TT (control)   *P*-HWE   Source   Quality   Genotyping
  -------------- ------ ----------- ----------------- ---------------------- -------------------- --------- -------- --------- ---------------------------
  Al-Dayel       2008   Asian       113-24-8          Lymphoma               389-113-8            0.95      PB       6         PCR-RFLP
  Canova         2009   Caucasian   1298-193-10       UADT                   1249-189-11          0.20      PB/HB    6         APEX
  De Mattia      2017   Caucasian   172-13-1          Liver cancer           182-10-0             0.71      PB       7         Pyrosequencing
  De Roos        2006   Caucasian   621-109-4         Lymphoma               537-83-6             0.17      PB       7         PCR
  Dura           2013   Caucasian   354-66-3          Esophageal cancer      485-91-5             0.46      PB       7         PCR
  Ebrahimkhani   2012   Asian       53-19-1           Colorectal cancer      83-12-0              0.51      HB       6         Pyrosequencing
  Garcia         2005   Caucasian   966-113-4         Bladder cancer         917-85-5             0.05      HB       6         Mixed assays
  Garcia         2012   Caucasian   500-56-1          Gastric cancer         500-57-0             0.20      PB       9         PCR-RFLP
  Ghatak         2016   Asian       44-20-16          Gastric cancer         68-12-0              0.47      PB       7         PCR-RFLP
  Harris         1998   Caucasian   113-17-1          Colorectal cancer      170-29-0             0.27      PB       7         PCR-RFLP
                                    154-28-2          Lung cancer            170-29-0             0.27      PB       7         PCR-RFLP
  Ibarrola       2012   Caucasian   516-38-1          Skin cancer            314-18-0             0.61      HB       5         TaqMan
  Jiao           2007   Caucasian   286-46-3          Pancreatic cancer      242-55-1             0.25      PB       7         Masscode system
  Krajinovic     2002   Caucasian   254-24-0          Leukemia               264-36-2             0.53      PB       6         ASO hybridization
  Kury           2008   Caucasian   882-137-4         Colorectal cancer      966-146-9            0.19      PB       7         Fluorescent multiplex PCR
  Landi          2005   Caucasian   325-35-0          Colorectal cancer      291-32-2             0.29      HB       5         APEX
  Landi          2007   Caucasian   80-7-1            MPM                    353-36-2             0.31      PB/HB    7         APEX
  Li             2010   African     85-49-7           Esophageal cancer      163-21-2             0.17      HB       6         PCR-RFLP
  Li             2007   Caucasian   678-114-11        Head and neck cancer   723-109-6            0.40      PB       8         PCR-RFLP
  Lira           2006   Caucasian   99-8-0            Skin cancer            112-18-0             0.40      HB       6         PCR-SSCP
  Marciniak      2006   Caucasian   81-15-7           Thyroid cancer         42-10-1              0.66      PB       7         PCR-RFLP
  Marshall       2000   Caucasian   35-13-0           Skin cancer            155-19-0             0.45      HB       6         PCR-SSCP
  Minina         2017   Caucasian   286-62-5          Lung cancer            239-56-5             0.42      PB       7         PCR
  Moore          2005   Mixed       591-103-6         Colorectal cancer      596-114-4            0.56      PB       7         TaqMan
  Murphy         2007   Caucasian   170-34-3          Esophageal cancer      190-31-2             0.56      PB       8         Multiplex PCR
  Northwood      2010   Caucasian   254-53-1          Colorectal cancer      233-60-3             0.69      PB       8         Multiplex PCR
  Oskina         2014   Caucasian   305-66-3          Prostate cancer        277-60-6             0.20      PB       6         TaqMan
  Park           1999   African     47-3-1            Oral cancer            81-2-0               0.91      HB       6         PCR-RFLP
                        Caucasian   93-8-2            Oral cancer            139-23-1             0.96      HB       6         PCR-RFLP
  Rajesh         2018   Asian       67-18-5           Oral cancer            167-12-1             0.15      PB       9         PCR-RFLP
  Saarikoski     1998   Caucasian   169-36-1          Lung cancer            241-51-1             0.35      PB       6         PCR-RFLP
  Sainz          2011   Caucasian   1480-275-10       Colorectal cancer      1472-291-21          0.13      PB       7         KASPar assay
  Siraj          2008   Asian       30-8-2            Thyroid cancer         389-113-8            0.95      PB       6         PCR-RFLP
  Sorensen       2004   Caucasian   216-36-1          Lung cancer            224-38-4             0.12      PB       6         PCR
  Stanulla       2000   Caucasian   52-11-1           Leukemia               48-16-0              0.25      HB       6         PCR-RFLP
  Van            2008   Caucasian   328-56-2          Breast cancer          337-47-1             0.63      HB       6         PCR-SSCP
                        African     49-5-0            Breast cancer          70-4-0               0.81      HB       6         PCR-SSCP
  Wadelius       1999   Caucasian   143-25-3          Prostate cancer        120-28-0             0.20      PB       5         PCR-SSCP
  Wang           2011   Asian       261-38-3          Colorectal cancer      263-27-1             0.73      PB       7         PCR-RFLP
  Wang           2003   Caucasian   468-108-3         Lung cancer            511-84-3             0.82      PB       7         PCR-RFLP
  Welfare        1999   Caucasian   167-28-1          Colorectal cancer      148-25-0             0.31      PB       6         PCR-RFLP
  Yang           2004   Mixed       192-32-5          Lung cancer            189-38-2             0.55      PB       6         PCR
  Zienolddiny    2008   Caucasian   250-60-9          Lung cancer            333-46-2             0.76      PB       7         APEX
                                                                                                                               

UADT, upper aerodigestive tract cancer; MPM, malignant pleural mesothelioma; HWE, Hardy--Weinberg equilibrium; PB, population-based control; HB, hospital-based control; PCR, polymerase chain reaction; RFLP, restriction fragment-length polymorphism; SSCP, single-strand conformation polymorphism; APEX, arrayed primer extension technique; ASO, allele-specific oligonucleotide.

Meta-Analysis Results
---------------------

First, we analyzed the relationship between the *GSTP1* rs1138272 polymorphism and the risk of cancer through a meta-analysis of the overall population. As shown in Table [2](#T2){ref-type="table"}, a total of 43 case-control studies with 15,688 cases and 17,143 controls were enrolled for the models of allele T vs. allele C, carrier T vs. carrier C, CT vs. CC, CT+TT vs. CC; in addition, 40 studies with 15,479 cases and 16,765 controls were enrolled for the models of TT vs. CC and TT vs. CC+CT. Because there was not a high degree of heterogeneity observed in the homozygote and recessive genetic models, a fixed-effects model was used in the Mantel--Haenszel statistics of association test for those genetic models. For the other genetic models, a random effects model was used in the DerSimonian and Laird statistics of association test. The quantitative synthesis results (Table [2](#T2){ref-type="table"}) revealed an increased risk for cancer, compared with the control group, for the genetic models of allele T vs. allele C (*P*-association = 0.007, OR = 1.17), carrier T vs. carrier C (*P*-association = 0.035, OR = 1.11), TT vs. CC (*P*-association = 0.002, OR = 1.45), TT vs. CC+CT (*P*-association = 0.009, OR = 1.42), and CT+TT vs. CC (*P*-association = 0.027, OR = 1.13). Nevertheless, no significant effect on cancer risk was observed for the model of CT vs. CC (Table [2](#T2){ref-type="table"}, *P*-association = 0.106). Supplementary Figures [S1](#FS1){ref-type="supplementary-material"}--[S4](#FS4){ref-type="supplementary-material"} presents the forest plot data under the allele, carrier, heterozygote and dominant models. In summary, the TT genotype of the *GSTP1* rs1138272 polymorphism may be associated with an increased susceptibility to cancer.

###### 

Meta-analysis of the overall population.

  Models                    Study(N)   Case(N)   Control(N)   I^2^    *P*-heterogeneity   Fixed/random   OR \[95% CI\]         *P*-association
  ------------------------- ---------- --------- ------------ ------- ------------------- -------------- --------------------- -----------------
  Allele T vs. allele C     43         15,688    17,143       67.1%   \<0.001             Random         1.17 \[1.04--1.31\]   0.007
  Carrier T vs. carrier C   43         15,688    17,143       47.9%   \<0.001             Random         1.11 \[1.02--1.22\]   0.035
  TT vs. CC                 40         15,479    16,765       28.6%   0.049               Fixed          1.45 \[1.14--1.83\]   0.002
  TT vs. CC+CT              40         15,479    16,765       25.0%   0.080               Fixed          1.42 \[1.12--1.80\]   0.009
  CT vs. CC                 43         15,688    17,143       52.5%   \<0.001             Random         1.09 \[0.98--1.21\]   0.106
  CT+TT vs. CC              43         15,598    16,963       61.4%   \<0.001             Random         1.13 \[1.01--1.27\]   0.027
                                                                                                                               

N, number;

P

-heterogeneity,

P

-value of heterogeneity test; OR, odds ratio; CI, confidence interval;

P

-association,

P

-value of association test.

Subgroup Analysis Results
-------------------------

Next, we performed three subgroup analyses based upon ethnicity (Table [3](#T3){ref-type="table"}), control source (Supplementary Table [S2](#TS2){ref-type="supplementary-material"}) and cancer type (Supplementary Table [S3](#TS3){ref-type="supplementary-material"}) in the overall population. As shown in Table [3](#T3){ref-type="table"}, similar positive results were detected in the subgroup "Asian" under the allele, homozygote, recessive and dominant models (Table [3](#T3){ref-type="table"}, all *P*-association \< 0.05, OR \> 1). As shown in Supplementary Table [S2](#TS2){ref-type="supplementary-material"}, we also assessed the difference between cancer cases and PB-based controls under the TT vs. CC (*P*-association = 0.006, OR = 1.45) and TT vs. CC+CT (*P*-association = 0.007, OR = 1.44) models. Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} present the relative forest plot of the subgroup analysis by ethnicity under the TT vs. CC and TT vs. CC+CT models, while Supplementary Figure [S5](#FS5){ref-type="supplementary-material"} shows the forest plot of subgroup analysis by control source under the TT vs. CC model. Moreover, compared with the controls, an increased cancer risk was observed in the "African" subgroup under all of the genetic models (Table [3](#T3){ref-type="table"}, all *P*-association \< 0.05, OR \> 1), but this was not the case for the "Caucasian" (Table [3](#T3){ref-type="table"}) and "Hospital-based, HB" (Supplementary Table [S2](#TS2){ref-type="supplementary-material"}) subgroups (all *P*-association \> or = 0.05). In addition, no significant association was found based on cancer type under most of the genetic models, except for the TT vs. CC (Supplementary Table [S3](#TS3){ref-type="supplementary-material"}, *P*-association = 0.001, OR = 3.11) and TT vs. CC+CT (*P*-association = 0.001, OR = 3.07) models of the "Head and neck cancer" subgroup. Supplementary Figure [S6](#FS6){ref-type="supplementary-material"} presents the forest plot of subgroup analysis by cancer type in the overall population under the allele T vs. allele C model, and Supplementary Table [S3](#TS3){ref-type="supplementary-material"} shows the pooled data of the "Colorectal cancer" subgroup with nine case-control studies (4,858 cases and 4,998 controls), the "Lung cancer" subgroup with seven case-control studies (2,123 cases and 2,266 controls) and the "Head and neck cancer" subgroup with six case-control studies (1,190 cases and 1,827 controls). Therefore, the rs1138272 polymorphism of the *GSTP1* gene appears to be correlated with an increased risk of cancer in the Asian and African populations. Moreover, the TT genotype of *GSTP1* rs1138272 may be associated with the risk of head and neck cancer in the overall population.

###### 

Subgroup analysis by ethnicity in the overall population.

  Subgroup    Models                    Study(N)   Case(N)   Control(N)   I^2^    *P*-heterogeneity   OR \[95% CI\]          *P*-association
  ----------- ------------------------- ---------- --------- ------------ ------- ------------------- ---------------------- -----------------
  Asian       Allele T vs. allele C     6          730       1,666        82.4%   \<0.001             2.20 \[1.26--3.84\]    0.006
              Carrier T vs. carrier C   6          730       1,666        71.4%   0.004               1.81 \[1.12--2.93\]    0.015
              TT vs. CC                 6          730       1,666        2.4%    0.401               6.51 \[3.36--12.60\]   \<0.001
              TT vs. CC+CT              6          730       1,666        0.0%    0.521               6.30 \[3.21--12.35\]   \<0.001
              CT vs. CC                 6          730       1,666        72.3%   0.003               1.61 \[0.96--2.73\]    0.074
              CT+TT vs. CC              6          730       1,666        78.9%   \<0.001             1.98 \[1.13--3.50\]    0.018
  Caucasian   Allele T vs. allele C     32         1,3783    1,4191       30.9%   0.051               1.04 \[0.95--1.13\]    0.406
              Carrier T vs. carrier C   32         1,3783    1,4191       0.2%    0.463               1.02 \[0.96--1.10\]    0.491
              TT vs. CC                 30         1,3628    1,3887       0.0%    0.495               1.00 \[0.76--1.31\]    0.991
              TT vs. CC+CT              30         1,3628    1,3887       0.0%    0.512               1.00 \[0.76--1.31\]    0.985
              CT vs. CC                 32         1,3783    1,4191       17.7%   0.190               1.03 \[0.95--1.12\]    0.472
              CT+TT vs. CC              32         1,3783    1,4191       24.2%   0.110               1.03 \[0.95--1.12\]    0.446
  African     Allele T vs. allele C     3          246       343          0.0%    0.517               3.66 \[2.34--5.71\]    \<0.001
              Carrier T vs. carrier C   3          246       343          0.0%    0.666               3.08 \[1.91--4.96\]    \<0.001
              TT vs. CC                 2          192       269          0.0%    0.885               6.38 \[1.53--26.56\]   0.011
              TT vs. CC+CT              2          192       269          0.0%    0.986               4.83 \[1.16--20.08\]   0.030
              CT vs. CC                 3          246       343          0.0%    0.437               3.77 \[2.27--6.28\]    \<0.001
              CT+TT vs. CC              3          246       343          0.0%    0.434               4.02 \[2.46--6.57\]    \<0.001
                                                                                                                             

N, number;

P

-heterogeneity,

P-

value of heterogeneity test; OR, odds ratio; CI, confidence interval;

P

-association,

P-

value of association test.

![Forest plot of the subgroup analysis by ethnicity in the overall population (TT vs. CC model).](fphys-09-01897-g002){#F2}

![Forest plot of the subgroup analysis by ethnicity in the overall population (TT vs. CC+CT model).](fphys-09-01897-g003){#F3}

Next, we performed subgroup analyses based upon control source (Supplementary Table [S4](#TS4){ref-type="supplementary-material"}) and cancer type (Supplementary Table [S5](#TS5){ref-type="supplementary-material"} and Supplementary Figures [S7](#FS7){ref-type="supplementary-material"}--[S10](#FS10){ref-type="supplementary-material"}), targeting the Caucasian population. Similar positive results were detected in the "Head and neck cancer" subgroup analysis (Supplementary Table [S5](#TS5){ref-type="supplementary-material"}). Even though no significant associations were found in the "PB" or "HB" subgroup analyses (Supplementary Table [S4](#TS4){ref-type="supplementary-material"}, all *P*-association \> 0.05), there was a positive association between *GSTP1* rs1138272 and the risk of colorectal cancer in the Caucasian population for the models of TT vs. CC (Supplementary Table [S5](#TS5){ref-type="supplementary-material"}, *P*-association = 0.52, OR = 1.21) and TT vs. CC+CT (*P*-association = 0.023, OR = 0.52). With regard to "Lung cancer," we observed a slightly increased risk in the Caucasian population under the models of allele T vs. allele C (*P*-association = 0.015, OR = 1.21), carrier T vs. carrier C (*P*-association = 0.044, OR = 1.18), CT vs. CC (*P*-association = 0.032, OR = 1.20), and CT+TT vs. CC (*P*-association = 0.020, OR = 1.22). Further, to eliminate the effects of the HB controls in the results of the Caucasian population, we also performed another subgroup analysis based upon cancer type using the Caucasian cases and population-based negative controls. Similar results were detected for colorectal and lung cancer (Supplementary Table [S6](#TS6){ref-type="supplementary-material"}). These data revealed that the TT genotype of the *GSTP1* rs1138272 polymorphism may decrease susceptibility to "Colorectal" cancers but increase susceptibility to "Head and neck" cancers, while the CT genotype may be associated with lung cancer risk in the Caucasian population.

Publication Bias and Sensitivity Analysis Results
-------------------------------------------------

In the meta-analysis of the overall population, the Begg's and Egger's tests revealed (Supplementary Table [S7](#TS7){ref-type="supplementary-material"}) a presence of potential publication bias for the allele model in the Begg's test (*P*-Begg's test = 0.028) or the allele (*P*-Egger = 0.013), carrier (*P*-Egger = 0.035), homozygote (*P*-Egger = 0.013), recessive (*P*-Egger = 0.013), and dominant (*P*-Egger = 0.046) models in the Egger's test. For the analysis targeting the Caucasian population (Supplementary Table [S8](#TS8){ref-type="supplementary-material"}), we only detected potential publication bias for the homozygote and recessive models (*P*-Egger \< 0.05; *P*-Egger \< 0.05). However, this slight publication bias only existed for the homozygote (*P*-Egger = 0.049) and recessive (*P*-Egger = 0.044) models using the Caucasian cases and population-based negative controls in the Egger's test (Supplementary Table [S9](#TS9){ref-type="supplementary-material"}). Figures [4A,B](#F4){ref-type="fig"} and Supplementary Figures [S11A,B](#FS11){ref-type="supplementary-material"}, [S12A,B](#FS12){ref-type="supplementary-material"} present the relative publication bias plots according to the Begg's tests as examples.

![The publication bias plot according to the Begg's test and the sensitivity analysis data for the overall population under the models of TT vs. CC and TT vs. CC+CT. **(A,B)** Begg's test; **(C,D)** sensitivity analysis.](fphys-09-01897-g004){#F4}

Additionally, we did not observe any remarkable alteration of the summary OR and corresponding 95% CI value when the individual case-control studies were removed one by one in our sensitivity analysis, confirming the abovementioned stability of the results. Some of the sensitivity analysis data (Figures [4C,D](#F4){ref-type="fig"} and Supplementary Figures [S11C,D](#FS11){ref-type="supplementary-material"}, [S12C,D](#FS12){ref-type="supplementary-material"}) are shown as examples.

Discussion
==========

The *GSTP1* rs1138272 polymorphism may be related to the risk of non-small cell lung cancer in the Norwegian population ([@B65]) and lung cancer in the Caucasian population of the United States ([@B55]). Nevertheless, no association was found between this polymorphism and lung cancer in Denmark ([@B47]) or with lung cancer in individuals in Russia who smoke ([@B32]). Hence, comprehensive analyses via the meta-analysis approach are meaningful.

In 2013, 28 case-control studies including 26 articles ([@B15]; [@B40]; [@B52]; [@B55], [@B53]; [@B2]; [@B47]; [@B60]; [@B11]; [@B23], [@B24]; [@B34]; [@B29]; [@B18]; [@B19]; [@B35]; [@B1]; [@B21]; [@B46]; [@B50]; [@B65]; [@B3]; [@B30]; [@B36]; [@B8]; [@B17]) were recruited into a meta-analysis performed by [@B16]. The results indicated that the *GSTP1* rs1138272 polymorphism appears to be associated with an increased risk of cancer, particularly lung cancer in the Asian population ([@B16]). In our analysis, we collected the available published articles as thoroughly as possible through a systematic search of five online electronic databases. The included case-control studies that were selected using our strict inclusion and exclusion criteria. We removed one case-control study in which the data were not in HWE ([@B30]), and we removed two additional studies ([@B2]) because they failed to meet the requirement of reporting the genotype frequency in both the case and control group. Moreover, 17 new articles ([@B38]; [@B56]; [@B31]; [@B48]; [@B20]; [@B5]; [@B28]; [@B26], [@B25]; [@B42]; [@B12]; [@B7]; [@B37]; [@B14]; [@B4]; [@B32]; [@B39]) were added. Finally, a total of 40 articles were included in our updated meta-analysis. After the data extraction, 43 case-control studies were enrolled in the meta-analysis under the allele, heterozygote, dominant, and carrier genetic models. All of the studies follow Hardy--Weinberg equilibrium and exhibit high quality. Three studies ([@B31]; [@B28]; [@B50]) were excluded in the homozygote and recessive models because the CC genotype frequency in both the case and control group was equal to zero. We detected a potential correlation between the TT genotype of *GSTP1* rs1138272 and cancer susceptibility in the Asian population, which is partly in agreement with the previously reported data ([@B16]). In addition, we found that the *GSTP1* rs1138272 polymorphism may be associated with an increased risk of cancer in the African population.

[@B61] recruited four case-control studies ([@B15]; [@B55]; [@B47]; [@B60]) to conduct a meta-analysis on the association between *GSTP1* rs1138272 and lung cancer risk ([@B61]). This group did not provide evidence for a strong association between *GSTP1* rs1138272 and lung cancer susceptibility ([@B61]). [@B59] included five case-control studies ([@B15]; [@B55]; [@B60]; [@B65]; [@B51]) to perform another relative meta-analysis ([@B59]) wherein an association between *GSTP1* rs1138272 and increased lung cancer risk was detected ([@B59]). Here, in our subgroup analysis of lung cancer, we removed one study that was not in HWE ([@B51]) and added two case-control studies ([@B40]; [@B32]) for the pooled analysis. Based on the available data within seven articles ([@B15]; [@B40]; [@B55]; [@B47]; [@B60]; [@B65]; [@B32]), we failed to detect a relationship between *GSTP1* rs1138272 and lung cancer risk in the overall population. However, when we enrolled the Caucasian cases and population-based negative controls in six studies ([@B15]; [@B40]; [@B55]; [@B47]; [@B65]; [@B32]) to perform another subgroup analysis by cancer type, we found that the CT genotype of *GSTP1* rs1138272 may confer the highest susceptibility to the lung cancer in the Caucasian population.

Previously, three meta-analyses of data on brain tumors were published ([@B22]; [@B10]; [@B13]). Each of these meta-analyses included four case-control studies ([@B9]; [@B6]; [@B57]; [@B43]). Unfortunately, based on our screening strategy, these studies could not be enrolled in our comprehensive analyses. One of the studies was not in HWE ([@B9]), and the others failed to provide the complete genotype frequency of CT and CT within *GSTP1* rs1138272 ([@B6]; [@B57]; [@B43]).

With regard to colorectal cancer, [@B27] performed a relevant meta-analysis including seven case-control studies (3,173 cases/3,323 controls) ([@B56]; [@B41]; [@B23]; [@B21]; [@B42]; [@B53]; [@B8]) in 2013 and reported a negative association between *GSTP1* rs1138272 and colorectal cancer risk ([@B27]). Herein, we ruled out one the studies included by [@B27] because it deviated from Hardy--Weinberg equilibrium ([@B41]), and we included three new eligible studies ([@B15]; [@B34]; [@B36]) to perform an updated analysis. Compared with the "colorectal cancer" subgroup of [@B16], two case-control studies ([@B56]; [@B42]) were added. Despite the additional studies, a similar negative conclusion in the overall population was observed in our updated meta-analysis. However, when targeting the Caucasian population, we found that the TT genotype of *GSTP1* rs1138272 may be positively linked to a decreased risk of colorectal cancer in Caucasians. Some environmental factors, such as nutrition and other exposures, may serve as the potential contributory reasons for the observed differences of susceptibility in different populations or cancers.

Although the results of the sensitivity analysis indicated the stability of the data, our study is not without several limitations. The issue of small sample sizes should be considered fully when interpreting certain results. For example, an elevated cancer risk was observed for the "African" subgroup under all of the genetic models; however, only two case-control studies were included for the homozygote and recessive models. Due to the lack of data, we had to consider all cancers together for the Asian and African populations. Despite the positive conclusions obtained, more case-control studies in the Asian and African population are warranted to enable more accurate cancer type-specific subgroup analyses.

Although we observed a potential relationship between *GSTP1* rs1138272 and the risk of colorectal, lung, head and neck cancers within Caucasians, no more than 10 case-control studies were enrolled, and more detailed head and neck cancer types were not evaluated due to the lack of sufficient data. Furthermore, the role of *GSTP1* rs1138272 in other cancer types has not yet been investigated. Only one case-control study was available for the stratified analysis of bladder, liver, or pancreatic cancer.

In addition, a high degree of inter-study heterogeneity and potential publication bias were observed in certain comparisons. The level of heterogeneity and publication bias was reduced in the analyses of the Caucasian population, suggesting that the "ethnicity" factor is essential for the assessment of the distinct role of *GSTP1* rs1138272 in cancer risk.

Considering the role of possible linkage disequilibrium in the genetic susceptibility to different cancers, we tried to extract the data of *GSTP1* haplotypes in the enrolled case-control studies. Nevertheless, not enough relevant data supported the performance of pooling analysis. In addition, the *GSTP1* rs1138272 polymorphism together with the *GSTM1* (glutathione *S*-transferase M1) null genotype was reported to be associated with the risk of colon or rectal cancer in the Indian population ([@B53]). The limited availability of useable data also prevented us from exploring the genetic effects of the *GSTP1* polymorphism combined with variants of other genes in specific cancer types. The factors, such as the age of onset, sex, lifestyle, environmental exposure, cancer source, linkage disequilibrium, synergistic interaction between genes, etiologies, relapses, and other patient clinical characterizations should be considered carefully when more data is available.

Above all, our pooled analysis consisting of the currently available eligible case-control studies demonstrated that the *GSTP1* rs1138272 polymorphism is associated with the susceptibility to overall cancer in the Asian and African populations and, moreover, this polymorphism may be linked to the risk of colorectal, lung or head and neck cancers in the Caucasian population. More eligible case-control studies containing cases with distinct cancers in various ethnic backgrounds are necessary for a more precise and relatively objective estimation.
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